<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03559660</url>
  </required_header>
  <id_info>
    <org_study_id>C87092</org_study_id>
    <nct_id>NCT03559660</nct_id>
  </id_info>
  <brief_title>CUP Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)</brief_title>
  <official_title>Compassionate Use Program Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma S.P.R.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <brief_summary>
    <textblock>
      The objective of this program is to allow treating physicians to supply/continue to supply&#xD;
      Certolizumab Pegol (CIMZIAÂ®, CZP) to adults suffering from Crohn's Disease (CD), and who are&#xD;
      considered not suitable for treatment, intolerant, have medical contraindications or had&#xD;
      insufficient response with an authorized conventional therapy, including other authorized&#xD;
      biologics.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Crohn's Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Certolizumab Pegol</intervention_name>
    <other_name>Cimzia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Patient comes from ending open label studies such as WELCOME -C87046, COSPAR - C87065,&#xD;
        MUSIC - C87043, PRECISE 3 - C87033, PRECISE 4 - C87034 and C87088&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient has been treated with any experimental biological or non biological therapy&#xD;
             other than Certolizumab Pegol (CZP) within 5 plasma half-lifes*&#xD;
&#xD;
          -  Has been treated with an approved biological, namely infliximab within the last 8&#xD;
             weeks, and adalimumab within the last 2 weeks*&#xD;
&#xD;
          -  Known hypersensitivity to CZP or any of its excipients&#xD;
&#xD;
          -  Current or recent history of severe, progressive, uncontrolled renal, hepatic,&#xD;
             haematological, gastrointestinal (other than Crohn's disease), endocrine, pulmonary,&#xD;
             cardiac, neurological, or cerebral disease&#xD;
&#xD;
          -  Serious or life threatening infection within the last 6 months, any signs of current&#xD;
             or recent infection&#xD;
&#xD;
          -  Active or latent tuberculosis (TB): if one or more of the 3 criteria is positive for&#xD;
             evidence of TB infection*:&#xD;
&#xD;
               1. A medical history of or a recent (&lt; 6 months) active tuberculosis (TB)&#xD;
&#xD;
               2. A recent (&lt;6 months) chest X-ray with signs consistent with TB infection&#xD;
&#xD;
               3. A recent (&lt;6 months) positive purified protein derivative (PPD) skin test&#xD;
                  (defined as induration or 5mm or more) and/or an indeterminate or positive&#xD;
                  QuantiFERON-TB Gold or Elispot test.&#xD;
&#xD;
        It is recommended that patients are monitored at least annually for active and latent TB by&#xD;
        both 1) a chest X-ray read by a pulmonologist or radiologist and 2) a PPD skin test and/or&#xD;
        Elispot/ QuantiFERON TB Gold test&#xD;
&#xD;
          -  Patient received live vaccinations including, but not limited to, oral polio, herpes&#xD;
             zoster, measles-mumps-rubella (MMR) or nasal influenza within the last 8 weeks or has&#xD;
             planned live immunizations during the planned period of administration of CZP&#xD;
&#xD;
          -  Known prior or concurrent viral hepatitis B and C&#xD;
&#xD;
          -  Known Human Immunodeficiency Virus (HIV) infection&#xD;
&#xD;
          -  Concurrent malignancy or a history of malignant disease&#xD;
&#xD;
          -  History of a lymphoproliferative disorder or any signs or symptoms suggestive of this&#xD;
             disease&#xD;
&#xD;
          -  History of, or suspected or confirmed active demyelinating disease of the central&#xD;
             nervous system&#xD;
&#xD;
          -  History of or concurrent New York Heart Association (NYHA) Class III/IV heart failure&#xD;
&#xD;
          -  As the safety and efficacy of CZP has not been established in patients younger than 18&#xD;
             years of age, drug is not recommended for use in these patients until further data are&#xD;
             available&#xD;
&#xD;
          -  As no data are available in pregnant women, drug should not be administered to female&#xD;
             patients of childbearing potential - unless an adequate method of contraception is&#xD;
             used - or to pregnant/lactating female patients.*&#xD;
&#xD;
        '*' Not applicable (NA) for patients on treatment with CZP from trials such as WELCOME&#xD;
        -C87046, COSPAR -C87065, MUSIC - C87043, PRECISE 3 - C87033, PRECISE 4 - C87034 and C87088.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>001 844 599 2273 (UCB)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>UCB Cares</last_name>
    <phone>+1 844 599</phone>
    <phone_ext>2273</phone_ext>
    <email>UCBCares@ucb.com</email>
  </overall_contact>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 5, 2018</study_first_submitted>
  <study_first_submitted_qc>June 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2018</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Certolizumab Pegol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

